Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandatory AE Information Requirements Needed For CAERS Filings – AHPA

This article was originally published in The Tan Sheet

Executive Summary

Adverse event reports should be required to contain certain information before being filed in the CFSAN Adverse Events Reporting System (CAERS), AHPA says in an Oct. 21 letter to the agency
Advertisement

Related Content

Mandatory Supplement AE Reporting Possible Under Current Law – AHPA
Mandatory Supplement AE Reporting Possible Under Current Law – AHPA
Mandatory Supplement AE Reporting Possible Under Current Law – AHPA
NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted
NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted
NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted
CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?
CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?
FDA Supplement AE Monitoring System Has "Six Problem Areas" - Burton

Topics

Advertisement
UsernamePublicRestriction

Register

PS094699

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel